Autolus Therapeutics (AUTL) Current Deferred Revenue (2021 - 2025)

Autolus Therapeutics (AUTL) has reported Current Deferred Revenue for 5 consecutive years, with $7.6 million the latest figure, recorded in Q3 2025.

• Quarterly Current Deferred Revenue fell 96.26% year-over-year to $7.6 million in Q3 2025, while the trailing twelve-month figure through Sep 2025 was $7.6 million (down 96.26% YoY) and the FY2022 annual result came in at $35.0 million, down 25.53% from the prior year.
• Current Deferred Revenue rose to $7.6 million in Q3 2025 per AUTL's latest filing, from $2.1 million in the prior quarter.
• Over the last five years, Current Deferred Revenue for AUTL reached as high as $203.4 million in Q3 2024 and fell as low as $2.1 million in Q2 2025.
• A 5-year average of $88.8 million and a median of $51.5 million in 2022 frame the typical range for Current Deferred Revenue.
• Annual changes were most pronounced in 2023 — Current Deferred Revenue jumped 168.7% — and 2025, when it slumped 98.93%.
• Year by year, Current Deferred Revenue stood at $47.0 million in 2021, then fell by 25.53% to $35.0 million in 2022, then surged by 302.29% to $140.8 million in 2023, then soared by 44.46% to $203.4 million in 2024, then plunged by 96.26% to $7.6 million in 2025.
• According to Business Quant data, Current Deferred Revenue over the past three periods registered $7.6 million, $2.1 million, and $4.7 million for Q3 2025, Q2 2025, and Q1 2025 respectively.